Involvement of the brain serotonergic system in the locomotor stimulant effects of chlorpheniramine in Wistar rats: Implication of postsynaptic 5-HT1A receptors

Behavioural Brain Research

Volumn 148, Issue 1-2, 2004, Pages 199-208

  Karamanakos, Petros N ^a   Pappas, Periklis ^a   Marselos, Marios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

8 OH DPAT; Brain; Chlorpheniramine; Hypothermia; Locomotion; Pindolol; Rat; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 HYDROXYINDOLEACETIC ACID; ANTIHISTAMINIC AGENT; CHLORPHENIRAMINE; DOPAMINE; MONOAMINE; NORADRENALIN; PINDOLOL; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; HYPOTHALAMUS; MALE; MESENCEPHALON; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SYNAPTIC TRANSMISSION;

EID: 0346995455     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00193-1     Document Type: Article

References (71)

1. Ahlenius S., Kaur P., Salmi P. Biphasic effects of 8-OH-DPAT on endurance of treadmill performance in the mail rat. Eur. Neuropsychopharmacol. 7:1997;89-94.
2. Bealer S.L. Histamine releases norepinephrine in the paraventricular nucleus/anterior hypothalamus of the conscious rat. J. Pharmacol. Exp. Ther. 264:1993;734-738.
3. 1A syndrome. Pharmacol. Biochem. Behav. 57:1997;897-908.
4. Bristow L.J., Bennett G.W. Biphasic effects of intraaccumbens histamine administration on spontaneous motor activity in the rat a role for central histamine receptors. Br. J. Pharmacol. 95:1988;1292-1302.
5. Bristow L.J., Bennett G.W. A role for histamine H3 receptors in histamine-induced hypoactivity in the rat. Br. J. Pharmacol. 94:1988;319P.
6. Cabrera-Vera T.M., Garcia F., Pinto W., Battaglia G. Neurochemical changes in brain serotonin neurons in immature and adult offspring prenatally exposed to cocaine. Brain Res. 870:2000;1-9.
7. Carruthers S.G., Shoeman D.W., Hignite C.E., Azarnoff D.L. Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin. Pharmacol. Ther. 23:1978;375-382.
8. Chiavegatto S., Nasello A.G., Bernardi M.M. Histamine and spontaneous motor activity: biphasic changes, receptors involved and participation of the striatal dopamine system. Life Sci. 62:1998;1875-1888.
9. 1A autoreceptor in vivo. Br. J. Pharmacol. 124:1998;206-212.
10. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Goodman Gilman A, Doodman LS, Rall TW, Murad F, editors. The pharmacological basis of therapeutics. 7th ed. New York: Macmillan; 1985. p. 605-38.
11. Dringenberg H.C., De Souza-Silva M.A., Rossmuller J., Huston J.P., Schwarting R.K. Histamine H1 receptor antagonists produce increases in extracellular acetylcholine in rat frontal cortex and hippocampus. J. Neurochem. 70:1998;1750-1758.
12. Dringenberg H.C., De Souza-Silva M.A., Schwarting R.K., Huston J.P. Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Naunyn Schmiedebergs Arch. Pharmacol. 358:1998;423-429.
13. Faingold CL. Antihistaminics as central nervous system depressants. In: Rocha e Silva M, editor. Handbook of experimental pharmacology, vol. 18. Berlin: Springer-Verlag; 1978. p. 561-71.
14. Fink J.S., Smith G.P. Decreased locomotor and investigatory exploration after denervation of catecholamine terminal fields in the forebrain of rats. J. Comp. Physiol. Psychol. 93:1979;34-65.
15. Geyer M.A., Puerto A., Menkes D.B., Segal D.S., Mandell A.J. Behavioral studies following lessions of the mesolimbic and mesostriatal serotonergic pathways. Brain Res. 106:1976;257-267.
16. Gillman P.K. The serotonin syndrome and its treatment. J. Psychopharmacol. 13:1999;100-109.
17. Grahame-Smith D.G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J. Neurochem. 18:1971;1053-1066.
18. Graudins A., Stearman A., Chan B. Treatment of the serotonin syndrome with cyproheptadine. J. Emerg. Med. 16:1998;615-619.
19. Hall L.M., Anderson G.M., Cohen D.J. Acute and chronic effects of fluoxetine and haloperidol on mouse brain serotonin and norepinephrine turnover. Life Sci. 57(8):1995;791-801.
20. Hillegaart V., Wadenberg M.L., Ahlenius S. Effects of 8-OH-DPAT on motor activity in the rat. Pharmacol. Biochem. Behav. 32:1989;797-800.
21. 2A/C receptors in the expression of patterns of spontaneous motor activity of the rat. Eur. J. Pharmacol. 295:1996;155-161.
22. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J.et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
23. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71:2002;533-554.
24. Huether G., Zhou D., Ryuther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (NDMA, "ecstasy") and its congeners. J. Neural. Transm. 104:1997;771-794.
25. Itowi N., Yamatodani A., Mochizuki T., Wada H. Effects of intracerebroventricular histamine injection on circadian activity phase entrainment during rapid illumination changes. Neurosci. Lett. 123:1991;53-56.
26. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine receptors and brain function. Neuropharmacology. 35:1996;1503-1519.
27. Jacobs B.L., Wise W.D., Taylor K.M. Differential behavioral and neurochemical effects following lessions of the dorsal or median raphe nuclei in rats. Brain Res. 79:1974;353-361.
28. Jacobs B.L., Fornal C.A. 5-HT and motor control: a hypothesis. Trends Neurosci. 16(9):1993;346-352.
29. 1A receptors. Naunyn Schmiedebergs Arch. Pharmacol. 352:1995;583-584.
30. Lidbrink P., Jonsson G., Fuxe K. The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology. 10:1971;521-536.
31. Lorens S.A., Guildberg H.C., Hole K., Kohler C., Srebro B. Activity, avoidance learning and regional 5-hydroxytryptamine following intra-brain stem 5,7-dihydroxytryptamine and electrolytic midbrain raphe lessions in the rat. Brain Res. 108:1976;97-113.
32. Lucki I., Nobler M.S., Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J. Pharmacol. Exp. Ther. 1:1984;133-139.
33. 1 antagonists as behavioral stimulants in the squirrel monkey. Psychopharmacology. 86:1985;380-381.
34. Meek J.L., Fuxe K., Carlsson A. Blockade of p-chloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. Biochem. Pharmacol. 20:1971;707-709.
35. Mefford I.N., Gilberg M., Barchas J.D. Simultaneous determination of catecholamines and unconjugated 3,4-dihydroxyphenylacetic acid (DOPAC) in brain tissue by ion-pairing reverse phase HPLC with electrochemical detection. Anal. Biochem. 104:1980;469-472.
36. Mefford I.N. Application of high performance chromatography with electrochemical detection to neurochemical analysis: measurement of catecholamines, serotonin and metabolites in rat brain. J. Neurosci. Methods. 3:1981;207-224.
37. Millan M.J., Rivet J.M., Canton H., Le Marouille-Girardon S., Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. J. Pharmacol. Exp. Ther. 264:1993;1364-1376.
38. Mountcastle VB. Sleep, wakefulness and the conscious state: intrinsic regulatory mechanisms of the brain. In: Mountcastle VB, editor. Medical physiology, vol. 1. St. Louis: C.V. Mosby Company; 1974. p. 254-84.
39. Niemegeers C.J.E., Awouters F.H.L., Janssen P.A.J. The in vivo pharmacological profile of histamine (H1) antagonists in the rat. Drug Dev. Res. 2:1982;559-566.
40. Nisijima K., Yoshino T., Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology. 150:2000;9-14.
41. 2-receptors agonists and antagonists after intraventricular infusion in fowls. Res. Commun. Chem. Pathol. Pharmacol. 27:1980;431-450.
42. 1A receptor activation. Br. J. Pharmacol. 106:1992;603-609.
43. 1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;140-144.
44. 1B receptors. Psychopharmacology. 132:1997;255-260.
45. Onodera K., Yamatodani A., Watanabe K., Wada H. Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog. Neurobiol. 42:1994;685-702.
46. Pitsikas N., Rigamonti A.E., Cella S.G., Locatelli V., Sala M., Muller E.E. Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. Eur. J. Pharmacol. 426:2001;193-200.
47. Radja F., Daval G., Hamon M., Verge D. Pharmacological and physicochemical properties of pre- versus postsynaptic 5-hydroxytryptamine1A receptor binding sites in the rat brain: a quantitative autoradiographic study. J. Neurochem. 58:1992;1338-1346.
48. Rajaofetra N., Sandillon F., Geffard M., Privat A. Pre- and post-natal ontogeny of serotonergic projections to the spinal cord. J. Neurosci. Res. 22:1989;305-321.
49. Romaniuk A., Koprowska M., Krotewicz M., Strzelczuk M., Wieczorek M. Effects of 8-OH-DPAT administration into the dorsal raphe nucleus and dorsal hippocampus on fear behavior and regional brain monoamines distribution in rats. Behav. Brain Res. 120:2001;47-57.
50. 1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res. 441:1988;403-407.
51. Sakurai E., Yamasaki S., Hikichi N., Onodera K. Effects of D- and DL-chlorpheniramine on serotonin and 5-hydroxyindoleacetic acid levels in the regional parts of rat brain. Yakubutsu Seishin Kodo. 11:1991;237-244.
52. Sansone M., Castellano C., D' Amato F.R. Enhancement of morphine-induced hyperactivity by antihistaminic drugs in mice. Arch. Int. Pharmacodyn. Ther. 284:1986;239-245.
53. Sansone M., D'Udine B., Renzi P., Vetulani J. Antihistaminics enhance morphine-, but not amphetamine- and scopolamine-induced hyperactivity in mice. Psychopharmacology. 93:1987;155-157.
54. Sansone M. Antihistaminic-opioid combination: effect on locomotor activity in mice. Pol. J. Pharmacol. Pharm. 40:1988;515-523.
55. Schwartz J.C., Arrang J.M., Garbarg M., Korner M. Properties and roles of the three subclasses of histamine receptors in brain. J. Exp. Biol. 124:1986;203-224.
56. Schwartz J.C., Arrang J.M., Garbarg M., Pollard H., Ruat M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 71:1991;1-51.
57. Segal D.S., Mandell A.J. Behavioral activation of rats during intraventricular infusion of norepinephrine. Proc. Natl. Acad. Sci. U.S.A. 66:1970;289-293.
58. Shishido S., Oishi R., Saeki K. In vivo effects of some histamine H1-receptor antagonists on monoamine metabolism in the mouse brain. Naunyn Schmiedebergs Arch. Pharmacol. 343(2):1991;185-189.
59. Sternbach H. The serotonin syndrome. Am. J. Psychiatry. 148:1991;705-813.
60. Takahashi H., Takada Y., Nagai N., Urano T., Takada A. Serotonergic neurons projecting to hippocampus activate locomotion. Brain Res. 869:2000;194-202.
61. Tuomisto L., Eriksson L. Cardiovascular and behavioural changes after i.c.v. infusions of histamine and agonists in conscious goat. Agents Actions. 10:1980;165-166.
62. Vanderwolf C.H. A general role for serotonin in the control of behavior: studies with intracerebral 5,7-dihydroxytryptamine. Brain Res. 504(2):1989;192-198.
63. Vanderwolf C.H., McLauchlin M., Dringenberg H.C., Baker G.B. Brain structures involved in the behavioral stimulant effect of central serotonin release. Brain Res. 772:1997;121-134.
64. Wauquier A., Niemegeers C.J.E. Effects of chlorpheniramine, pyrilamine and astemizole on intracranial self-stimulation in rats. Eur. J. Pharmacol. 72:1981;245-248.
65. Westlund K.N., Bowker R.M., Ziegler M.G., Coulter J.D. Descending noradrenergic projections and their spinal terminations. Prog. Brain Res. 57:1982;219-238.
66. Wirtshafter D., Montana W., Asin K.E. Behavioral and biochemical studies of the substrates of median raphe lession induced hyperactivity. Physiol. Behav. 38:1986;751-759.
67. Yeh S.H. Effects of antihistamines on fenfluramine-induced depletion of indoles in the brain of rats. Synapse. 32:1999;301-311.
68. Yeh S.Y., Dersch C., Rothman R., Cadet J.L. Effects of antihistamines on 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse. 33:1999;207-217.
69. 1 antagonist, confirmed by the use of D-chlorpheniramine with monitoring electroencephalography. Methods Find. Exp. Clin. Pharmacol. 15:1993;183-188.
70. Yokoyama H., Iinuma K. Histamine and seizures: implications for the treatment of epilepsy. CNS Drugs. 5:1996;321-330.
71. 1 antihistamines of the uptake of noradrenaline and 5-HT into rat brain synaptosomes. Biochem. Pharmacol. 37:1988;976-978.